Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s a new word for me.
Abstruse
MHRA:
”We will always prioritise applications according to public health need.”
Yes, ever since the 80 days passed, there is a chance that any business day could provide a decision. It gets more likely as each day passes.
He did Gary. 150 + 120 is 270.
The trial remained blinded prior to the protocol change. This happens quite often in trials. Not “Ex post facto.”
That Journal, BJC, only has an impact factor of 9.
Whereas
The Journal Impact Factor of 28.4 placed JAMA Oncology as one of the highest-ranking oncology journals.
Mar 21, 2024
That’s a shoddy review, not JAMA.
That is proven wrong by the recurrent data which used no chemo in the recurrent trial.
Pay attention instead of plagiarizing shoddy reviews.
The DCVax-l rGBM trial does not use chemo. Like almost all recurrent GBM trials, the DCVax-l rGBM trial starts after chemo has failed.
Dummkopf.
This helps show MOA and why checkpoint inhibitors could help:
1. T-cells infiltrate the tumor.
2. Obviously reduce t-cell exhaustion.
3. Reduce tumor assisted macrophages (TAM) in the tumor microenvironment.
BTW, you were right, your MHRA link is more up to date.
Digging into the Twitter thing further, I found that your MHRA link was still first, not MHRA Twitter.
Maybe, but I think the next list, for the last half of March, gets published on Monday.
I was thinking of MarauderWarlock’s post instead. Apologies.
Thinking about this just announced policy more, I wonder if it might (also) prevent intimidation by third parties.
Product approval announcements
We have continued work to publish announcements to coincide with the conclusion of regulatory assessments, delivering on a key objective as listed within our corporate plan to build public trust and understanding of our work.
These are issued simultaneously as outcomes are communicated to applicants…. MHRA, March 2024
Just an observation. MHRA converted from publishing their product marketing approvals from every month to every 14 days on October 1, 2022.
BTW, I think this might be the better link.
https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2024
I was talking to somebody about the photographer’s picture of his dying daughter in agony from cancer.
There was a deck of cards nearby.
I said, imagine this deck of cards could cure cancer if used in the right way, but you need the whole deck.
The fundamental problem is that large pharma does not want to cure cancer. They instead see massive economic opportunity by dividing the cards up amongst all the BP. I started throwing cards down individually and in clusters.
The person I was speaking with said, I get it, I get it.
That is their cynical economic model.
I’m not certain. If they already submitted or extremely close (fda) and CRL is ready, then maybe artisan first here, but I kinda doubt it. I think commercial artisan serves a purpose at Advent — parallel testing Eden.
NWBO is so close to the vest.
Not my wheelhouse.
Doc or anybody else, the press release on the Eden prototype being assigned to a device manufacturer was a bit vague on dates.
It is my contention that this was done earlier than the beginning of February. I think it was probably done by at least December 20, if not earlier.
I assume the contractor considers this high priority. I assume Flaskworks and Dr. Bosch visit often to consult and provide feedback.
I assume the device manufacturer is efficient at what they do.
Sure would like to know who it is, but I’d reckon nwbo starts testing the commercial version by sometime in June.
It sounds more immediate.
CRL/cognate might be ready. We don’t know.
I could guess, but…. better not.
Yeah, until I read the March 28 MHRA newsletter, I had no idea MHRA might beat NWBO to any announcement. Maybe I read it wrong.
??? “as the data is being presented to the FDA”
???
This is from the March 28, 2024 MHRA Newsletter.
Product approval announcements
We have continued work to publish announcements to coincide with the conclusion of regulatory assessments, delivering on a key objective as listed within our corporate plan to build public trust and understanding of our work.
These are issued simultaneously as outcomes are communicated to applicants, and we work in tandem with the company and across the health systems and health technology assessment bodies ahead of issuing press materials. Products we have recently communicated about include diagnostic tools for people with heart disease and prostate cancer; a treatment for ulcerative colitis that both NICE and the MHRA have simultaneously published their recommendations on, and a first anti-seizure medication to treat patients with rare epileptic seizure disorder.
Prior experience:
Laura Posner
Prior to joining the firm, Laura was appointed by the New Jersey Attorney General to serve as the Bureau Chief for the New Jersey Bureau of Securities – the top securities regulator in New Jersey. In that capacity, she was responsible for administrating and enforcing the New Jersey Uniform Securities Law and regulations thereunder, as well as managing and overseeing the employees who staff the Bureau of Securities. Cases prosecuted under Laura’s direction as Bureau Chief resulted in hundreds of millions of dollars in recoveries for New Jersey residents and more than 20 criminal convictions.
Stonkmaster has a question or FOI out to CHM. I doubt they’ll tell him anything.
With prior regulators.
I do believe NWBO and advent did everything humanly possible to line up matters and prepare so that an RFI would be less likely, or at least very small in scope.
I mean, it seemed like they were getting Apollo 11 ready.
It does not. At least not in any time window that matters. Imo.
Great. Have a good one.
ChatGPT
When a public company sues market makers over spoofing allegations, it is typically the responsibility of state authorities or regulatory bodies such as the Securities and Exchange Commission (SEC) or the Commodity Futures Trading Commission (CFTC) to investigate and take appropriate actions.
State authorities, such as state attorney generals, may also have jurisdiction over market manipulation cases within their respective states. These authorities have the power to investigate allegations, gather evidence, and potentially take legal action against market makers if they find evidence of wrongdoing.
The SEC and CFTC are federal regulatory agencies that oversee the securities and commodities markets, respectively. They have the authority to enforce regulations, investigate allegations of market manipulation, and impose penalties or sanctions on market participants found guilty of misconduct, including spoofing.
It is important to note that each case is unique, and the involvement of authorities may vary depending on the specific circumstances and jurisdictions involved. Allegations of spoofing against market makers are typically taken seriously by both state and federal authorities, who work to ensure the integrity and fairness of the financial markets.
That has nothing to do with what you asked and what I cited.
Chat GPT
Naked shorts refer to short positions where the trader sells shares without actually borrowing them. In some cases, naked shorts may need to borrow shares before they can cover their positions. This can happen if the broker requires the trader to have the shares in their account in order to close the position. However, it's important to note that naked short selling is generally prohibited or heavily regulated in many jurisdictions. The specific rules and requirements for covering naked shorts can vary depending on the regulations in place.
Today you didn’t deny being Michonne, and Michonne was Pyrr.
Pyrrhonian
Re: A deleted message
Saturday, 06/04/2016 8:41:24 AM
Lol awesome. I'm okay with you guys thinking I'm every new poster that ever takes an interest in NWBO. It makes for very funny reading. But if you want to know the truth, there aren't that many. Pyrrhonian, jmlogan (made to debate AVII), Michonne (made to debate stuff I temporarily agreed not to under my Pyrr handle), and finishedworks and egkainia are two yahoo handles I've had forever. It just depends on which email account I checked last before writing a YMB message. I don't even think about finished vs egkainia handles.
There ya go, that's all of em. As with NWBO, you can accept the truth, or you can create and hang on to innumerable fantasies instead.
Yeah, but I was Raven Seldon* on a different site, many years ago.
You are Pyrr, Michonne and inquirig on this site. In obvious violation of TOS.
(*Can’t wait for season 3)
Thanks for the riveting entomology, Michonne. 🙄
Mr. Junorama stating August.